⌘K
t
Allergy Therapeutics plc announced on 12 March 2026 that ZQ Group undertook an internal re-organisation on 25 February 2026, involving the transfer of 2,144,399,381 shares between various SkyGem entities within the group. Separately, SkyGem International Holdings Limited placed 209,600,000 shares to four investors at an average price of 10 pence per share on 27 February and 2 March 2026. Following these transactions, ZQ Capital and related entities hold 3,831,131,532 shares, representing 60.5% of Allergy Therapeutics' issued share capital.
| Date | 12 Mar 2026 |
| Time | 07:00:12 |
| Category | Director/PDMR dealings |
| ID | 3113W |
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
PDMR Dealings & Shareholding Update
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that the Company has been notified by ZQ Group of the following.
A re-organisation took place within ZQ Group which involved the transfer of the majority of the Company's shares previously held by SkyGem Acquisition Limited to SkyGem International Holdings Limited, both entities being within ZQ Group (the "Transfer"). The Transfer was undertaken to optimise ZQ's internal holding structure of AGY shares. The Transfer did not result in any change to the ultimate beneficial ownership of Allergy Therapeutics plc.
Separately, SkyGem International Holdings Limited placed an aggregate of 209,600,000 shares to four investors at an average price of 10 pence per share. The shares placed are in the paper form and are restricted from trading in the AIM market within the twelve months following the placement. The placement was designed to optimise the shareholder base ahead of the Company's earlier announced plan of a potential dual listing in Hong Kong.
Following these transactions, ZQ Capital and related entities hold the following shares in Allergy Therapeutics plc:
|
Holding entity |
Number of shares |
|
SkyGem International Holdings Ltd |
3,828,575,524 |
|
SkyGem Acquisition Ltd |
2,150,665 |
|
ZQ Capital Ltd |
315,343 |
|
Shen Zheqing |
90,000 |
|
Total |
3,831,131,532 |
The aggregate holdings above represent 60.5% of the Company's issued share capital.
As a result of these transactions, Zheqing (Simon) Shen, a person discharging managerial responsibilities ("PDMR") by virtue of his position as a director of the Company, has notified the Company of the following dealings.
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus Fricker
Nigel Birks - Life Science Specialist Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.
Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
ZQ Capital Management Limited |
|
|
2 |
Reason for the notification |
|
|
|
a) |
Position/status |
Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy Therapeutics Plc. |
|
|
b) |
Initial notification/Amendment |
Initial notification. |
|
|
3 |
Details of the issuer, UK emission allowance market participant, auction platform or auctioneer |
||
|
a) |
Name |
Allergy Therapeutics Plc |
|
|
b) |
LEI |
213800PQ7AHK7KGVOE23 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
|
Ordinary shares |
|
|
b) |
Nature of the transaction |
(1) Transfers between SkyGem Acquisition Ltd to SkyGem International Holdings Ltd (2) Transfers between SkyGem Acquisition Ltd to SkyGem UK Holding Ltd (3) Transfers between SkyGem UK Holding Ltd to SkyGem International Holdings Ltd (4) Sale of Ordinary Shares
|
|
|
c) |
Price(s) and volume(s) |
Price(s) (1) £0.1080 (1) £0.0228 (2) £0.0228 (3) £0.0228 (4) $0.1087 (4) £0.1020 (4) $0.1086 (4) $0.1085
|
Volume(s) (1) 150,925,926 (1) 1,993,473,455 (2) 1,893,776,143 (3) 1,893,776,143 (4) 1,840,000 (4) 189,334,000 (4) 3,684,000 (4) 14,742,000
|
|
|
|
||
|
|
|||
|
d) |
Aggregated information · - Aggregated volume · - Price |
(1) 2,144,399,381 Ordinary Shares (2) 1,893,776,143 Ordinary Shares (3) 1,893,776,143 Ordinary Shares (4) 209,600,000 Ordinary Shares
(1) £0.0288 per share (2) £0.0228 per share (3) £0.0228 per share (4) £0.100 per share |
|
|
e) |
Date of the transaction |
(1) 25/02/2026 (2) 25/02/2026 (3) 25/02/2026 (4) 27/02/2026, 27/02/2026, 02/03/2026, 27/02/2026
|
|
|
f) |
Place of the transaction |
Outside a trading venue. |
|